Novo Nordisk heeds KBP Biosciences’ CLARION call
Novo Nordisk’s metabolic juggernaut semaglutide is known to work in chronic kidney disease – but the group appears to want a back-up plan.
You may also be interested in...
Plus deals involving BioLineRx/GloriaBio, Healios/Athersys, Aurobindo/Hilleman, Lupin/Menarini, GC Biopharma/Immetas, CanariaBio, Specialised Therapeutics, TaiGen/Y.S.P., Nippon/Kayaku/Adlai Nortye, WuXi/PharmaEssentia, Evommune/Maruho and Ono/Adimab.
The Danish giant’s GLP-1 agonist blockbuster is effective against diabetes, obesity and cardiovascular disease. Now kidney disease can be added to the list after a Phase III trial was halted for efficacy.
The fortunes of the foundation that controls Novo Nordisk and backs a wide range of scientific, humanitarian and social causes are set to be transformed by the spectacular commercial success of the weight loss blockbuster Wegovy.